Intelligent Investors Den!
Sign up Now and Gain Access to Exciting Opportunities from Investor and Resource Space!
By submitting your details and clicking on the SIGN UP button you agree to Kalkine’s Free Trial-Terms of Use and consent to receive marketing offers including to be contacted by email or phone, as set out in our Privacy Policy Any calls will be made by Kalkine Pty Ltd or Kalkine Solutions Private Limited on our behalf. You also agree that Kalkine/KSPL can give you its Financial Services Guide by electronic means (including by website link or email). Before accessing our services, please read the Financial Services Guide available here.
By creating account you will get access to hot stocks & personalised emails
Any calls will be made by Kalkine Pty Ltd or Kalkine Solutions Private Limited on our behalf.
Important notice: Some features of our site are currently unavailable. Our team is actively working on resolving the issue. We apologize for any inconvenience this may have caused.
Note: Kalkine Pty Limited (“Kalkine”) may display, include or make available third-party content including charts or any other data (“Third Party Content”) on its website/app. You acknowledge and agree that Kalkine is not responsible for Third Party Content including their accuracy, content, reliability or any other aspect thereof. Kalkine will not accept liability for any loss or damage, including without limitation any loss of profit, which may arise directly or indirectly from use of or reliance on such Third Party Content. All Third Party Content is the exclusive property of their respective owners.
CSL Limited develops, manufactures and markets human and veterinary pharmaceutical and diagnostic products derived from human plasma. The company markets its products - human and animal vaccines, antibiotics and anticoagulants – nationally and internationally. Recently the company has acquired Telecris in the US subject to regulatory approval. The Company is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company operates in three segments: CSL Behring, Intellectual Property Licensing and Other Human Health. CSL Behring manufactures markets and develops plasma products. Intellectual Property Licensing includes revenue and associated expenses from the licensing of Intellectual Property generated by the Group to unrelated third parties. Other Human Health consists of CSL Bio plasma and CSL Biotherapies. These businesses manufacture and distribute bio therapeutic products. It operates in four geographic areas: Australia, the United States of America, Switzerland, and Germany. Its subsidiaries include CSL Employee Share Trust, CSL Biotherapies Pty Ltd, Cervax Pty Ltd, CSL Biotherapies (NZ) Limited, Iscotec AB, Zenyth Therapeutics Pty Ltd, CSL International Pty Ltd and CSL Finance Pty Ltd.
45 Poplar Rd, Parkville, VIC, 3052
Phone: +61 3 9389 1911
Email: [email protected]
Website: www.csl.com.au
© Data powered by Morningstar, Inc. 2023. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy andTerms and Conditions Allow cookies Decline